Adoptive immunotherapy for cancer: building on success - Wikidata - awgldk - TriplyDB

Adoptive immunotherapy for cancer: building on success

Adoptive immunotherapy for cancer: building on success

http://www.wikidata.org/entity/Q24546258

about

Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells Immunological interactions in radiotherapy-opening a new window of opportunity Recent advances in the field of anti-cancer immunotherapy Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention Adoptive cell therapy for sarcoma Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic Immunotherapy for Bone and Soft Tissue Sarcomas Harnessing the Microbiome to Enhance Cancer Immunotherapy Early experience with novel immunomodulators for cancer treatment A human memory T cell subset with stem cell-like properties TGF-beta: a mobile purveyor of immune privilege Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.Age-dependent tolerance to an endogenous tumor-associated antigen.In vivo imaging of T cell delivery to tumors after adoptive transfer therapy.Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.T-cell artificial focal triggering tools: linking surface interactions with cell response.Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.NKG2D CARs as cell therapy for cancer.A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.

P2860

Q23918376-887F1EDC-5E91-47DA-951D-F4CAE9591E6A Q24596055-93DF8D24-C5C2-47D7-8E43-0715A1AB9DD8 Q24615166-BC440BE5-9366-4902-B309-449FEC25EC00 Q24623215-B3D33AE5-49C0-4D14-9494-3264A329D427 Q24633445-D63C3E11-06AC-4B57-AB52-4209CF7B714E Q24648424-B4AB24AA-7DEF-4C2E-9A7C-ACBFBDF293BD Q24651232-211582D8-C51B-47E9-9030-6A9402F1983D Q26767178-8183341E-342F-4F11-A50A-F4BC6BE290AC Q26775602-B5BC0247-BA43-4463-91D0-93C43CBF9EC6 Q26850218-0127D7CB-2F3B-4D34-8808-C46BA5C2AC75 Q27009541-8DE833E6-075F-469F-955F-B27DE567949B Q28068378-B2E133D7-6595-434E-BD1C-455ECDF22394 Q28074619-DABC405E-9467-4881-97BD-F7A6A9A288DB Q28075992-11FF9E53-5F9C-4619-86E9-A9E09F2BF73E Q28088363-0F09F339-35F9-4633-9C65-A811A92A81DE Q28088598-76B22134-0FC3-4964-9846-1A3234DFD296 Q28241744-EF41D9A7-A2E6-44B0-8308-93055D36A53D Q28248395-AF1B8F40-DC7E-4F26-9C3B-178EF3CE6CE8 Q28263622-CAC75E21-A87A-49E0-AF92-927250149057 Q28659468-93561105-C9FD-4A8F-ABA2-0248775F6C3F Q28732041-CF2774AF-75C0-4CF3-9E53-B27C276D4A4E Q29622835-B9FE5E9D-D464-4C35-968B-C5678DCF2755 Q30430002-1B84DDCE-1D70-43DF-BCBA-0E551670F913 Q30439993-A91C6F5B-7EDE-41DA-9EAA-F79CD238D13D Q30479855-A389B2ED-2723-4F8E-AC0E-22EA19AEBF8A Q30481516-77071ED8-C3CE-4FD2-8BB5-772E4D3708C0 Q30573747-69363DA7-AA76-478B-B839-0957C372D87C Q30830664-AF2CEF3A-5E47-417B-A7CB-F0875F5DCF91 Q33261122-853D2748-3EAB-41AA-A182-A5B63C43C7F2 Q33282703-892EA0D0-8C33-47C7-AE71-2F9546E159E9 Q33289956-01C95F2E-9C0C-419C-A105-DDB6B27E16D4 Q33413155-142E8D7D-45D0-43B3-AE29-373E15E9F882 Q33416441-BDDD482E-C497-47B3-9E37-9963415A5A05 Q33530146-D84438A8-B239-474D-8B65-6E9416CD8D4C Q33558482-AD96DFBF-19E3-4953-B495-6BCCDAACC24A Q33573323-EF644F60-F274-4472-BF9C-923C490D6D69 Q33582300-18B4489D-7F90-48B4-B770-CC0494FDA264 Q33584851-1E73489F-54D4-4E6C-B7A4-0DB267D42227 Q33595873-1213DE95-A9A8-48C8-A020-DF1673E36F5B Q33638509-5826C089-D93D-4F35-B6EC-0204950AE18E

P2860

Adoptive immunotherapy for cancer: building on success

http://www.wikidata.org/entity/Q24546258

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Adoptive immunotherapy for cancer: building on success

@ast

Adoptive immunotherapy for cancer: building on success

@en

Adoptive immunotherapy for cancer: building on success

@nl

type

label

Adoptive immunotherapy for cancer: building on success

@ast

Adoptive immunotherapy for cancer: building on success

@en

Adoptive immunotherapy for cancer: building on success

@nl

prefLabel

Adoptive immunotherapy for cancer: building on success

@ast

Adoptive immunotherapy for cancer: building on success

@en

Adoptive immunotherapy for cancer: building on success

@nl

P1433

Q24546258-84A70D58-70F4-4B2C-860A-6FF7DF3D14C9

P1476

Q24546258-B234A62E-8C92-42E3-8207-A576F5240978

P2093

Q24546258-73808266-9B42-4B1A-9739-A67C74F17AAC

Q24546258-857AB8A1-76C9-4213-8714-8646FA889736

Q24546258-A1B828A4-B589-416E-837F-F9C1CDFC2B92

Q24546258-B71D3C55-363C-4D69-A11D-EA0D7D290A66

P2860

Q24546258-063B1EB3-4A44-47C3-8F61-CCDD0FCBD953

Q24546258-0789D973-C369-48ED-890E-37B46559968A

Q24546258-081A53FC-A0A7-4A16-8814-A22680633B9B

Q24546258-0ADB510A-4123-4E78-8803-3101FAB92C3E

Q24546258-0AE8C676-FC4E-4068-A913-93091A63FEE1

Q24546258-0B4C9E17-1EE3-40F0-B806-87A420EA5CA9

Q24546258-0BE62F50-6902-48DB-826E-CDDCBCE1542C

Q24546258-0C93C411-890E-4F66-8A90-4C50E6A627AE

Q24546258-0F4B13CB-C144-4144-93C9-708E7F96DA4B

Q24546258-10B0696B-03B8-41F9-B116-4DCDE90721F1

P2888

Q24546258-0D31A264-A1A2-484A-B6BC-96107176E67D

P304

Q24546258-B78090D5-6CCA-4597-8B3B-2055E0B94655

P31

Q24546258-CEC6DD63-B396-4D69-881D-5C552B25417D

P3181

Q24546258-CECDE061-7C03-46C1-A59C-66922F4AF9F4

P356

Q24546258-0C41B6EE-E17A-436E-AB4F-B27CA3C84F5A

P407

Q24546258-6253A868-4985-4FE4-9D44-678599971BE5

P433

Q24546258-F6C58F37-4925-4212-8365-26F6ADCDAB1D

P478

Q24546258-CEA9745C-343F-4FD4-BD74-7859D4882900

P577

Q24546258-ABAFCCAA-961A-4C2D-988C-8836168907ED

P5875

Q24546258-5ED4B95C-3C0A-4117-8A9F-68260D270A9D

P6179

Q24546258-07A0388D-9DB3-4DD2-8DAC-B6A2CEF73AC1

P698

Q24546258-B4DF839B-93E9-4794-BCA1-9B060390F1D5

P921

Q24546258-DEA78DDC-0F3F-409A-AA63-4834C5B137AD

P932

Q24546258-66AF7541-1B63-4C06-BC97-382846EA0BB9

P3181

P356

P1433

Nature Reviews Immunology

P1476

Adoptive immunotherapy for cancer: building on success

@en

P2093

Daniel J Powell

http://www.w3.org/2001/XMLSchema#string

Luca Gattinoni

http://www.w3.org/2001/XMLSchema#string

Nicholas P Restifo

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation

CD28/B7 system of T cell costimulation

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer immunotherapy: moving beyond current vaccines

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells

P2888

P304

383-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2698281

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRI1842

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7158766

http://www.w3.org/2001/XMLSchema#string

P6179

1036296603

http://www.w3.org/2001/XMLSchema#string

P698

16622476

http://www.w3.org/2001/XMLSchema#string

P921

P932

1473162

http://www.w3.org/2001/XMLSchema#string